Zacks: Homology Medicines (FIXX) Given $30.67 Consensus Target Price by Brokerages

Homology Medicines (NASDAQ:FIXX) has received a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price objective of $30.67 for the company and are forecasting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Homology Medicines an industry rank of 231 out of 255 based on the ratings given to related companies.

A number of equities research analysts have weighed in on FIXX shares. Bank of America started coverage on shares of Homology Medicines in a report on Monday, April 23rd. They set a “buy” rating and a $27.00 target price on the stock. BTIG Research started coverage on shares of Homology Medicines in a report on Tuesday, April 24th. They set a “buy” rating and a $35.00 target price on the stock. Cowen started coverage on shares of Homology Medicines in a report on Monday, April 23rd. They set an “outperform” rating on the stock. Finally, Evercore ISI started coverage on shares of Homology Medicines in a report on Monday, April 23rd. They set an “outperform” rating and a $30.00 target price on the stock.

In other news, insider James E. Flynn acquired 1,250,000 shares of Homology Medicines stock in a transaction dated Monday, April 2nd. The shares were bought at an average cost of $16.00 per share, with a total value of $20,000,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Vida Ventures, Llc acquired 375,000 shares of Homology Medicines stock in a transaction dated Monday, April 2nd. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $6,000,000.00. The disclosure for this purchase can be found here.

Several large investors have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in shares of Homology Medicines in the 1st quarter valued at $1,700,000. Nexthera Capital LP bought a new stake in shares of Homology Medicines in the 1st quarter valued at $243,000. Blackstone Group L.P. bought a new stake in shares of Homology Medicines in the 1st quarter valued at $252,000. Rock Springs Capital Management LP bought a new stake in shares of Homology Medicines in the 1st quarter valued at $10,753,000. Finally, Acuta Capital Partners LLC bought a new stake in shares of Homology Medicines in the 1st quarter valued at $1,477,000. 48.46% of the stock is currently owned by institutional investors.

Homology Medicines traded up $0.16, reaching $19.84, during trading on Friday, Marketbeat.com reports. 181,900 shares of the company were exchanged, compared to its average volume of 143,620. Homology Medicines has a twelve month low of $16.12 and a twelve month high of $24.40.

Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Monday, May 14th. The company reported ($4.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($3.78) by ($0.43). The business had revenue of $0.82 million for the quarter. research analysts expect that Homology Medicines will post -1.74 earnings per share for the current fiscal year.

Homology Medicines Company Profile

There is no company description available for Homology Medicines Inc

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply